This is the same population as in the lecanemab trials ... No patients on subcutaneous remy had systemic reactions, though three of the 15 participants developed mild injection-site reactions, such as ...

In recent years, lecanemab, a drug that removes amyloid beta, has attracted attention. However, there are concerns about its side effects, such as brain swelling and bleeding. A possible drug ...

All investors want to make sure that we maximize the organic growth represented by ENHANZE and our auto-injectors by ... as a 20 to 30 second subcutaneous injection, which is administered by ...

News of the death of the 65-year-old woman, who was receiving lecanemab as part of the CLARITY-AD trial, first emerged in November shortly after the top-line results from the study were revealed.

Its approval succeeds both the FDA’s accelerated and traditional approvals of Eisai and Biogen’s lecanemab (also known as Leqembi), a similar treatment, in early and mid-2023 respectively.

In addition, our program to support the launch of POV with the subcutaneous auto injector for monthly at-home administration is well underway. And for full approval, we are making strong progress ...

The company offers multiple coverage types, but its auto insurance is available only to paid AAA members. All AAA memberships come with several perks and discount opportunities, but coverage ...

Montway Auto Transport is a nationwide company offering fast and reliable vehicle and motorcycle moving services. The company ships more than 250,000 vehicles annually and offers efficient auto ...

In addition, our program to support the launch of POV with the subcutaneous auto injector for monthly at-home administration is well underway. And for full approval, we are making strong progress ...

It has been doing this for more than 30 years and its work has resulted in five licensed medicines, including cancer drug pembrolizumab and lecanemab for Alzheimer’s disease. LifeArc's goal is a world ...

The OKO auto-injector. [Image courtesy of IDE Group] IDE Group recently unveiled OKO, its new ophthalmic auto-injector for improving drug delivery precision and efficiency. The company says OKO ...

We present clinical outcomes from episodes of care using subcutaneous continuous subcutaneous infusion of furosemide (CSCI-furosemide). Methods Retrospective review of service improvement data. The ...